Travere Therapeutics
Travere Therapeutics is a patient-centered biopharmaceutical company committed to making a difference for people living with rare kidney disease.
Last updated September 1, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Travere Therapeutics is a patient-centered biopharmaceutical company that stands with rare disease communities. It focuses on developing therapies for rare kidney diseases and other rare conditions. The company has received FDA approval for FILSPARI (sparsentan) in FSGS and IgA Nephropathy, and has a pipeline including treatments for Classical Homocystinuria, Cystinuria, and other conditions.
History
Travere Therapeutics is a patient-centered biopharmaceutical company that stands with rare disease communities. It is committed to developing therapies for rare diseases, with a focus on rare kidney disease. The company has received FDA approval for FILSPARI (sparsentan) in FSGS and IgA Nephropathy, and has a pipeline including treatments for Classical Homocystinuria, Cystinuria, and other conditions.
Products and positioning
FILSPARI (sparsentan)
First and only approved medicine for FSGS, also approved for IgA Nephropathy.
Thiola
Registered trademark of Travere Therapeutics.
Thiola EC
Registered trademark of Travere Therapeutics.
Sources4 sources
Cite this profile: Cite the canonical profile. /brand-wiki/travere-therapeutics · Editorial policy · How profiles are compiled